Otsuka's drug, Voyxact, has shown some effectiveness in slowing the loss of kidney function in patients suffering from chronic autoimmune kidney disease during a one-year trial.
While the results indicate a positive impact on kidney function preservation, they were not as significant as researchers had hoped.
The findings highlight the ongoing challenges in developing effective treatments for chronic kidney conditions, as expectations for Voyxact's performance were not fully realized.